Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations

Rogers, J.K., McMurray, J.J.V. , Pocock, S.J., Zannad, F., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J. and Pitt, B. (2012) Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation, 126(19), pp. 2317-2323. (doi:10.1161/CIRCULATIONAHA.112.110536)

Full text not currently available from Enlighten.

Abstract

Background—Eplerenone is known to reduce time to first hospitalization for heart failure or cardiovascular death in patients with heart failure and mild symptoms. In chronic diseases such as heart failure, characterized by repeat hospitalizations, analyzing all heart failure hospitalizations, not just the first, should give a more complete picture of treatment benefits. Methods and Results—The Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF) trial compared eplerenone with placebo in 2737 patients with mild heart failure, followed for a median 2.08 years (interquartile range, 1.08–3.10 years). Data were collected on all hospitalizations, with a focus on those due to heart failure. Heart failure hospitalization rates in the eplerenone and placebo groups were 10.70 and 16.99 per 100 patient-years, respectively. Allowing for skewness in the frequency of hospitalizations by using the negative binomial generalized linear model, the rate ratio (eplerenone versus placebo) was 0.53 (95% confidence interval, 0.42–0.66; P<0.0001). A plot of cumulative hospitalization rates over time revealed that most of the reduced risk on eplerenone occurred in the first year of follow-up. Several baseline variables strongly predicted the risk of hospitalization. More complex statistical methods, adjusting for mortality (as informative censoring), made a negligible difference in these findings. Conclusions—Eplerenone markedly reduces the risk of heart failure hospitalizations in patients with heart failure and mild symptoms to a greater extent than is captured by only studying the time to first hospitalization. Future clinical trials in heart failure would gain from incorporating repeat hospitalizations into their primary evaluation of treatment effects.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Rogers, J.K., McMurray, J.J.V., Pocock, S.J., Zannad, F., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J., and Pitt, B.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Circulation
ISSN:0009-7322
Published Online:05 October 2012

University Staff: Request a correction | Enlighten Editors: Update this record